Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and ...

Upstream Bio completed Phase 2 trial enrollment for verekitug and raised $293 million in an IPO, funding operations through 2027. Upstream Bio, Inc. announced the completion of patient enrollment in ...

– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary ...

Upstream Bio is presenting at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, which highlights the company's commitment to disseminating important research and gaining ...

Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to a loss of $0.51 per share a year ago. These figures ...

Shares of inflammatory disease biotech Upstream Bio, Inc. (UPB) have rallied by roughly 60% since reporting potentially best-in-class data for its asset verekitug in a Phase 2 trial in early September ...

Regulatory approval is only one marker of success for biotherapeutics. Biotherapeutics must also be commercially feasible. Too high a price tag can lead to limited availability to the targeted patient ...

Dublin, May 21, 2026 (GLOBE NEWSWIRE) -- The "Upstream and Downstream Manufacturing in the Biopharmaceutical Industry (June 11, 2026)" training has been added to ResearchAndMarkets.com's offering.

The intensification of upstream bioprocessing sounds daring, as though it were equivalent to flooring a car’s accelerator pedal and pushing the tachometer into the red zone. But with the right ...